Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.